{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:53:20Z","timestamp":1790974400305,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Turku","id":[{"id":"https:\/\/ror.org\/05vghhr25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET\/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET\/CT with\n                      <jats:sup>18<\/jats:sup>\n                      F-DCFPyL and\n                      <jats:sup>18<\/jats:sup>\n                      F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1365 lesions were identified in 39 patients.\n                      <jats:sup>18<\/jats:sup>\n                      F-DCFPyL PET\/CT detected 1351 lesions (99%). In contrast,\n                      <jats:sup>18<\/jats:sup>\n                      F\u2013FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p\u2009&lt;\u20090.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on\n                      <jats:sup>18<\/jats:sup>\n                      F-DCFPyL PET\/CT was 85\u00a0mL and on\n                      <jats:sup>18<\/jats:sup>\n                      F-FAPI-74 PET\/CT only 10\u00a0mL (p\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In mPC, PSMA PET\/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration: EudraCT<\/jats:title>\n                    <jats:p>2022\u2013003788-13. Registered 21 September 2023<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08028-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:30:19Z","timestamp":1782441019000},"page":"6837-6848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of [18F]DCFPyL and [18F]FAPI-74 PET\/CT imaging in metastatic prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-2788","authenticated-orcid":false,"given":"Anniina","family":"Hyv\u00e4kk\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-2445","authenticated-orcid":false,"given":"Marko","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-2965","authenticated-orcid":false,"given":"Maria","family":"Sundvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veera","family":"Sivonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-9187","authenticated-orcid":false,"given":"Kalle","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-7177","authenticated-orcid":false,"given":"Mikael","family":"Anttinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-4602","authenticated-orcid":false,"given":"Otto","family":"Ettala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-9231","authenticated-orcid":false,"given":"Mikael","family":"H\u00f6german","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-2973","authenticated-orcid":false,"given":"Anna","family":"Kirjavainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-5662","authenticated-orcid":false,"given":"Olli","family":"Eskola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-7895","authenticated-orcid":false,"given":"Sarita","family":"Forsback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-5924","authenticated-orcid":false,"given":"Virva","family":"Saunavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-0510","authenticated-orcid":false,"given":"Samuli","family":"Arvola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusti","family":"Kilpinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-4604","authenticated-orcid":false,"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-8978","authenticated-orcid":false,"given":"Simona","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-4333","authenticated-orcid":false,"given":"Heikki","family":"Minn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"1","key":"8028_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020;77(1):38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"key":"8028_CR2","doi-asserted-by":"publisher","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S; ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","DOI":"10.1016\/j.annonc.2020.06.011"},{"issue":"9","key":"8028_CR3","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.3390\/cancers13092244","volume":"13","author":"A Hyv\u00e4kk\u00e4","year":"2021","unstructured":"Hyv\u00e4kk\u00e4 A, Virtanen V, Kemppainen J, Gr\u00f6nroos TJ, Minn H, Sundvall M. More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond. Cancers (Basel). 2021;13(9):2244. https:\/\/doi.org\/10.3390\/cancers13092244.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8028_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2967\/jnumed.121.263262","volume":"63","author":"H Jadvar","year":"2022","unstructured":"Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022;63(1):59\u201368. https:\/\/doi.org\/10.2967\/jnumed.121.263262.","journal-title":"J Nucl Med"},{"key":"8028_CR5","doi-asserted-by":"publisher","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"8028_CR6","doi-asserted-by":"publisher","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;16;385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","DOI":"10.1056\/NEJMoa2107322"},{"issue":"6","key":"8028_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2967\/jnumed.121.263274","volume":"63","author":"H Jadvar","year":"2022","unstructured":"Jadvar H. The VISION Forward: Recognition and Implication of PSMA-\/18F-FDG+ mCRPC. J Nucl Med. 2022;63(6):812\u20135. https:\/\/doi.org\/10.2967\/jnumed.121.263274.","journal-title":"J Nucl Med"},{"issue":"2","key":"8028_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"8028_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"8028_CR10","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020;61(8):1171\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.236786.","journal-title":"J Nucl Med"},{"key":"8028_CR11","doi-asserted-by":"publisher","unstructured":"Singh SB, Shrestha BB, Gandhi OH, Shah RP, Mukhtiar V, Ayubcha C, Desai V, Eberts CE, Paudyal P, Jha G, Singh A, Shi Y, Kumar T. The comparative utility of FAPI-based PET radiotracers over [18F]FDG in the assessment of malignancies. Am J Nucl Med Mol Imaging. 2024;14(4):190\u2013207. https:\/\/doi.org\/10.62347\/JXZI9315.","DOI":"10.62347\/JXZI9315"},{"key":"8028_CR12","doi-asserted-by":"publisher","unstructured":"Lanzafame H, Mavroeidi IA, Pabst KM, Fragoso Costa P, Schuler M, Bauer S, Kurth J, Heuschkel M, Siveke JT, Herrmann K, Kostbade K, Kersting D, Leyser S, Fr\u00f6hling S, Heilig CE, Hamacher R, Fendler WP.\u00a090Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis. J Nucl Med. 2026 Feb 19:jnumed.125.271135. https:\/\/doi.org\/10.2967\/jnumed.125.271135.","DOI":"10.2967\/jnumed.125.271135"},{"issue":"12","key":"8028_CR13","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2967\/jnumed.124.268386","volume":"65","author":"A Helisch","year":"2024","unstructured":"Helisch A, Kratochwil C, Kleist C, Kr\u00e4mer S, Rosales Castillo JJ, Dendl K, et al. Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage. Progressive Metastatic Tumors J Nucl Med. 2024;65(12):1917\u201322. https:\/\/doi.org\/10.2967\/jnumed.124.268386.","journal-title":"Progressive Metastatic Tumors J Nucl Med"},{"issue":"1","key":"8028_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","volume":"49","author":"C Kesch","year":"2021","unstructured":"Kesch C, Yirga L, Dendl K, Handke A, Darr C, Krafft U, et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021;49(1):385\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05423-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8028_CR15","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","volume":"47","author":"EG Isik","year":"2022","unstructured":"Isik EG, Has-Simsek D, Sanli O, Sanli Y, Kuyumcu S. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET\/CT. Clin Nucl Med. 2022;47(1):e54\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000003837.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"8028_CR16","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47(8):2040\u20131. https:\/\/doi.org\/10.1007\/s00259-019-04623-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8028_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"8028_CR18","doi-asserted-by":"publisher","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u20131638. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","DOI":"10.1007\/s00259-021-05245-y"},{"issue":"6","key":"8028_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"issue":"3","key":"8028_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12149-021-01702-8","volume":"36","author":"K Kessel","year":"2022","unstructured":"Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med. 2022;36(3):293\u2013301. https:\/\/doi.org\/10.1007\/s12149-021-01702-8.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"8028_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13402-023-00872-z","volume":"47","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Tao J, Qiu J, Cao Z, Huang H, Xiao J, et al. From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment. Cell Oncol (Dordr). 2024;47(2):361\u201381. https:\/\/doi.org\/10.1007\/s13402-023-00872-z.","journal-title":"Cell Oncol (Dordr)"},{"issue":"12","key":"8028_CR22","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.2967\/jnumed.124.268037","volume":"65","author":"RR Huang","year":"2024","unstructured":"Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, et al. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024;65(12):1952\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.268037.","journal-title":"J Nucl Med"},{"issue":"1","key":"8028_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/genes13010135","volume":"13","author":"PJ Vlachostergios","year":"2022","unstructured":"Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival. Genes (Basel). 2022;13(1):135. https:\/\/doi.org\/10.3390\/genes13010135.","journal-title":"Genes (Basel)"},{"key":"8028_CR24","doi-asserted-by":"publisher","unstructured":"Luboldt W, Z\u00f6phel K, Wunderlich G, Abramyuk A, Luboldt HJ, Kotzerke J. Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET\/CT. Mol Imaging Biol. 2010;12(1):78\u201384. https:\/\/doi.org\/10.1007\/s11307-009-0230-3.","DOI":"10.1007\/s11307-009-0230-3"},{"issue":"6","key":"8028_CR25","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar2080","volume":"8","author":"S Bauer","year":"2006","unstructured":"Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8(6):R171. https:\/\/doi.org\/10.1186\/ar2080.","journal-title":"Arthritis Res Ther"},{"issue":"21","key":"8028_CR26","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/eurheartj\/ehq519","volume":"32","author":"CE Brokopp","year":"2011","unstructured":"Brokopp CE, Schoenauer R, Richards P, Bauer S, Lohmann C, Emmert MY, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J. 2011;32(21):2713\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehq519.","journal-title":"Eur Heart J"},{"key":"8028_CR27","doi-asserted-by":"publisher","unstructured":"Novruzov E, Sheikh GT, Mamlins E, Holzgreve A, Mori Y, Ledderose S, Klauschen F, Watabe T, Gorin MA, Pomper MG, Herrmann K, Rowe SP, Werner RA, Giesel FL. Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0. J Nucl Med. 2025;66(8):1245\u20131251. https:\/\/doi.org\/10.2967\/jnumed.125.269914.","DOI":"10.2967\/jnumed.125.269914"},{"issue":"4","key":"8028_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/ph18040522","volume":"18","author":"W Serumula","year":"2025","unstructured":"Serumula W, Pillay V, Hadebe B, Vorster M. Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics. Pharmaceuticals (Basel). 2025;18(4):522. https:\/\/doi.org\/10.3390\/ph18040522.","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08028-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:02:18Z","timestamp":1790971338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8028"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08028-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by National Committee on Medical Research Ethics (Tukija, tukija.fi\/en\/frontpage) (3.7.2023, T\/153\/2022).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      and\n                      \n                      .","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}